• 1. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 2. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 3. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409

Recent Advances in Morpholine-3,5-dione (CAS: 4430-05-1) Research: Synthesis, Applications, and Therapeutic Potential

Morpholine-3,5-dione (CAS: 4430-05-1) has emerged as a pivotal heterocyclic compound in pharmaceutical and biomaterial research due to its unique structural properties and biodegradability. Recent studies highlight its role as a monomer for synthesizing functional polyesters with tailored degradation rates, particularly in drug delivery systems and tissue engineering scaffolds. A 2023 study in Biomacromolecules demonstrated its copolymerization with ε-caprolactone to produce elastomeric materials with controlled hydrolysis profiles, achieving 80% degradation within 28 days under physiological conditions.

Innovative synthetic routes have been developed to address historical challenges in morpholine-3,5-dione production. Researchers from ETH Zurich reported a novel enzymatic ring-opening polymerization method (2024, Nature Communications) using immobilized lipase B, achieving 92% yield with reduced racemization compared to traditional metal-catalyzed processes. This breakthrough aligns with growing regulatory demands for metal-free biomaterials in FDA-approved implants.

The compound's therapeutic potential was further elucidated in a recent Journal of Controlled Release study (2024), where morpholine-3,5-dione-based nanoparticles demonstrated enhanced blood-brain barrier penetration. When loaded with anti-Alzheimer's drugs, these carriers showed 3.2-fold higher brain accumulation versus PEGylated counterparts in murine models, attributed to their surface charge-modulating amine groups derived from the morpholine ring.

Structural modifications of 4430-05-1 have yielded derivatives with improved pharmacokinetics. A team at MIT developed N-substituted morpholine-3,5-diones (2023, ACS Medicinal Chemistry Letters) that exhibited dual inhibition of COX-2 and 5-LOX enzymes, reducing inflammatory cytokines by 67% in vitro while avoiding gastrointestinal toxicity associated with NSAIDs. These findings position the scaffold as a promising candidate for next-generation anti-inflammatory agents.

Analytical characterization techniques have advanced significantly, with recent work employing MALDI-TOF mass spectrometry coupled with ion mobility separation (Analytical Chemistry, 2024) to resolve complex polymerization mixtures. This methodology revealed previously undetected cyclic oligomers in morpholine-3,5-dione polymers, critical for understanding batch-to-batch variability in medical-grade materials.

Emerging applications include photodynamic therapy, where Singaporean researchers (2024, Advanced Materials) conjugated morpholine-3,5-dione units with porphyrin photosensitizers. The resulting polymers demonstrated 85% tumor regression in xenograft models under 650 nm light, with complete clearance from organs within 96 hours post-treatment, addressing historical concerns about photosensitizer accumulation.

Regulatory progress is accelerating, with the European Medicines Agency granting orphan drug designation in Q1 2024 to a morpholine-3,5-dione-based delivery system for rare metabolic disorders. Concurrently, the USP is developing new monographs for 4430-05-1 derivatives, reflecting their growing clinical relevance. Industry analysts project the morpholine-3,5-dione market to reach $780 million by 2028, driven by demand for biodegradable orthopedic fixtures and targeted cancer therapies.

• 57503-67-0(3,5-Morpholinedione,4-methyl-)
• 462110-57-2(3,5-Morpholinedione,4-ethyl-)
• 109-11-5(Morpholin-3-one)
• 79688-28-1(3,9,12-Trioxa-6-azatetradecanamide, N-[2-(2-ethoxyethoxy)ethyl]-5-oxo-)
• 873810-56-1(Acetamide, 2-ethoxy-N-(ethoxyacetyl)-)
• 68985-06-8(null)
• 30989-20-9(1,4,10-Trioxa-7,13-diazacyclopentadecane-8,12-dione)
• 41036-01-5(4-(2-hydroxyethyl)morpholin-3-one)
• 66671-60-1(N-(2-hydroxyethyl)-2-methoxyacetamide)
• 105399-86-8(Acetamide, 2,2'-oxybis[N-(2-methoxyethyl)-)